BCL2 G101V	Chronic Lymphocytic Leukemia	BCL2 G101V	Chronic Lymphocytic Leukemia	venetoclax + rituximab Resistant: C3 – Early Trials venetoclax + rituximab Resistant : C3	venetoclax + rituximab Resistant: C3 – Early Trials venetoclax + rituximab Resistant : C3
BCL2 G101V	Chronic Lymphocytic Leukemia	BCL2 G101V	Chronic Lymphocytic Leukemia	venetoclax + obinutuzumab Resistant: C3 – Early Trials venetoclax + obinutuzumab Resistant : C3	venetoclax + obinutuzumab Resistant: C3 – Early Trials venetoclax + obinutuzumab Resistant : C3
BCL2 G101V	Chronic Lymphocytic Leukemia	BCL2 G101V	Chronic Lymphocytic Leukemia	BGB-11417 Sensitive: D – Preclinical BGB-11417 Sensitive : D	BGB-11417 Sensitive: D – Preclinical BGB-11417 Sensitive : D
BCL2 G101V	Chronic Lymphocytic Leukemia	BCL2 G101V	Chronic Lymphocytic Leukemia	venetoclax Resistant: D – Preclinical venetoclax Resistant : D	venetoclax Resistant: D – Preclinical venetoclax Resistant : D

BCL2 G101V

Associations